V116 designed to target serotypes that account for 85% of all invasive pneumococcal disease in individuals aged 65 and over in the United States as of 2019
LYNPARZA is approved in the U.S. for patients with HRR gene-mutated mCRPC (BRCA-mutated and other HRR gene mutations)
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
We see significant potential in working with oncolytic virus companies and Neo antigen-companies
First and only FDA-approved device of its kind demonstrates consistently high rates of target limb salvage and freedom from clinically-driven target lesion revascularization
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
India’s first oncology laboratory for comprehensive Cancer Diagnostic services
Dasatinib Tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive
Amarex Clinical Research guides its client to phase II of FDA trials
The production and supply in Canada are designed to address the growing need for no-carrier-added Lutetium-177 (n.c.a. Lu-177) in North America
Subscribe To Our Newsletter & Stay Updated
